Ester Verdaguer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ester Verdaguer has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Carme Auladell
University of Barcelona
4 shared publications - Antoni Camins
Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain
3 shared publications - Miren Ettcheto
Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, Universitat de Barcelona, Barcelona, Spain; Institute of Neurosciences, Universitat de Barcelona, Barcelona, Spain; Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Carlos III Health Institute, Madrid, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
3 shared publications - Oriol Busquets
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Rose F. Kennedy Center, Albert Einstein College of Medicine
2 shared publications Adolfo López de Munain
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBER-CIBERNED), ISCIII, Madrid 28031, Spain
1 shared publication- Anna M. Aragay
Department of Biomedicine, University of Bergen, Bergen, Norway
1 shared publication
Latest Publications
- 6 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (822) , eabq1007
A mammalian-specific Alex3/Gα q protein complex regulates mitochondrial trafficking, dendritic complexity, and neuronal survival
Mitochondrial dynamics and trafficking are essential to provide the energy required for neurotransmission and neural activity. We investigated how G protein–coupled receptors (GPCRs) and G proteins control mitochondrial dynamics and trafficking. The activation of Gα q inhibited mitochondrial trafficking in neurons through a mechanism that was independent of the canonical downstream PLCβ pathway. Mitoproteome analysis revealed that Gα q interacted with the Eutherian-specific mitochondrial protein armadillo repeat–containing X-linked protein 3 (Alex3) and the Miro1/Trak2 complex, which acts as an adaptor for motor proteins involved in mitochondrial trafficking along dendrites and axons. By generating a CNS-specific Alex3 knockout mouse line, we demonstrated that Alex3 was required for the effects of Gα q on mitochondrial trafficking and dendritic growth in neurons. Alex3-deficient mice had altered amounts of ER stress response proteins, increased neuronal death, motor neuron loss, and severe motor deficits. These data revealed a mammalian-specific Alex3/Gα q mitochondrial complex, which enables control of mitochondrial trafficking and neuronal death by GPCRs.
- 6 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (822) , eabq1007
A mammalian-specific Alex3/Gα q protein complex regulates mitochondrial trafficking, dendritic complexity, and neuronal survival
Mitochondrial dynamics and trafficking are essential to provide the energy required for neurotransmission and neural activity. We investigated how G protein–coupled receptors (GPCRs) and G proteins control mitochondrial dynamics and trafficking. The activation of Gα q inhibited mitochondrial trafficking in neurons through a mechanism that was independent of the canonical downstream PLCβ pathway. Mitoproteome analysis revealed that Gα q interacted with the Eutherian-specific mitochondrial protein armadillo repeat–containing X-linked protein 3 (Alex3) and the Miro1/Trak2 complex, which acts as an adaptor for motor proteins involved in mitochondrial trafficking along dendrites and axons. By generating a CNS-specific Alex3 knockout mouse line, we demonstrated that Alex3 was required for the effects of Gα q on mitochondrial trafficking and dendritic growth in neurons. Alex3-deficient mice had altered amounts of ER stress response proteins, increased neuronal death, motor neuron loss, and severe motor deficits. These data revealed a mammalian-specific Alex3/Gα q mitochondrial complex, which enables control of mitochondrial trafficking and neuronal death by GPCRs.
- Open Access
- 4 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S378-S379
LICOCHALCONE A AS A POTENTIAL MULTI-TARGET DRUG AGAINST COGNITIVE DYSFUNCTION IN LPS-INDUCED NEUROINFLAMMATION MICE MODEL
- 4 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S378-S379
Open AccessLICOCHALCONE A AS A POTENTIAL MULTI-TARGET DRUG AGAINST COGNITIVE DYSFUNCTION IN LPS-INDUCED NEUROINFLAMMATION MICE MODEL
- Open Access
- 5 July 2020
- Published by Universidad Autonoma del Estado de Hidalgo in Mexican Journal of Medical Research ICSA
- Vol. 8 (16) , 5-12
JNK isoforms control mammal adult hippocampal neurogenesis
In mammals, the term “adult hippocampal neurogenesis” defines the process through which, throughout adulthood, new granular neurons are produced by neural stem cells (NSC) in the subgranular zone (SGZ) in the dentate gyrus (DG) of the hippocampus or, by a population of immature neurons located in the SGZ. Either way, the existence of neurogenic activity in the hippocampus has been correlated with learning, memory formation and behavioral responses to stress, together with the pathophysiology of many brain diseases and mood disorders. Various extracellular and intracellular stimuli have been shown to modulate survival, proliferation, and differentiation of adult-born cells in the hippocampus especially, through conserved stimuli-response mechanisms like the JNKs, which have been described as regulators of adult neurogenesis. In the present review, the JNK pathway and their control of adult hippocampal neurogenesis is described, evidencing the critical role of JNK1 in this process.
- 5 July 2020
- Published by Universidad Autonoma del Estado de Hidalgo in Mexican Journal of Medical Research ICSA
- Vol. 8 (16) , 5-12
Open AccessJNK isoforms control mammal adult hippocampal neurogenesis
In mammals, the term “adult hippocampal neurogenesis” defines the process through which, throughout adulthood, new granular neurons are produced by neural stem cells (NSC) in the subgranular zone (SGZ) in the dentate gyrus (DG) of the hippocampus or, by a population of immature neurons located in the SGZ. Either way, the existence of neurogenic activity in the hippocampus has been correlated with learning, memory formation and behavioral responses to stress, together with the pathophysiology of many brain diseases and mood disorders. Various extracellular and intracellular stimuli have been shown to modulate survival, proliferation, and differentiation of adult-born cells in the hippocampus especially, through conserved stimuli-response mechanisms like the JNKs, which have been described as regulators of adult neurogenesis. In the present review, the JNK pathway and their control of adult hippocampal neurogenesis is described, evidencing the critical role of JNK1 in this process.
- 6 May 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (12) , 1286-1299
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease
: Late-onset Alzheimer’s disease (LOAD) is a neurodegenerative disorder that has become a worldwide health problem. This pathology has been classically characterized for its affectation on cognitive function and the presence of depositions of extracellular amyloid β-protein (Aβ) and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau protein. To this day, no effective treatment has been developed. : Multiple strategies have been proposed over the years with the aim of finding new therapeutic approaches, such as the sequestration of Aβ in plasma or the administration of anti-inflammatory drugs. Also, given the significant role of the insulin receptor in the brain in the proper maintenance of cognitive function, drugs focused on the amelioration of insulin resistance have been proposed as potentially useful and effective in the treatment of AD. In the present review, taking into account the molecular complexity of the disease, it has been proposed that the most appropriate therapeutic strategy is a combinatory treatment of several drugs that will regulate a wide spectrum of the described altered pathological pathways.
- 6 May 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (12) , 1286-1299
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease
: Late-onset Alzheimer’s disease (LOAD) is a neurodegenerative disorder that has become a worldwide health problem. This pathology has been classically characterized for its affectation on cognitive function and the presence of depositions of extracellular amyloid β-protein (Aβ) and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau protein. To this day, no effective treatment has been developed. : Multiple strategies have been proposed over the years with the aim of finding new therapeutic approaches, such as the sequestration of Aβ in plasma or the administration of anti-inflammatory drugs. Also, given the significant role of the insulin receptor in the brain in the proper maintenance of cognitive function, drugs focused on the amelioration of insulin resistance have been proposed as potentially useful and effective in the treatment of AD. In the present review, taking into account the molecular complexity of the disease, it has been proposed that the most appropriate therapeutic strategy is a combinatory treatment of several drugs that will regulate a wide spectrum of the described altered pathological pathways.